RLMD logo

Relmada Therapeutics (RLMD)

Profile

Full Name

Relmada Therapeutics, Inc.

Ticker Symbol

RLMD

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

June 20, 2014

Indexes

Not included

Website

http://www.relmada.com

Employees

17

Key Details

Price

$0.31(+2.33%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$2.65(+19.21% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.31
RLMD price is $0.31

30-Day Relative Volume

0.68
RLMD 30-day relative volume is 0.68

Price Performance

Price Most recent change

+2.33%
RLMD price was up +2.33% on Apr 15, 2025

Price YTD change

-40.77%
RLMD price is down -40.77% since January 1st

Price 1-year change

-93.08%
RLMD price is down -93.08% year-on-year

Price 3-year change

-98.82%
RLMD price is down -98.82% over the past 3 years

Price Range

Price All-time high

$80.00
RLMD price is currently -99.61% below its historical high of $80.00

Price 3-year low

$0.24
RLMD price is currently +28.33% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$10.22M
RLMD market capitalization is $10.22 million

Market cap 3-year change

-98.67%
RLMD market capitalization is down -98.67% over the past 3 years

Market cap All-time high

$1.06B
RLMD market capitalization is currently -99.04% below its historical high of $1.06 billion

Market cap sector rank

20.07%
RLMD market capitalization is higher than 20.07% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+10%
RLMD shares outstanding is up +10% year-on-year

Shares Outstanding 3-Year Change

+12.77%
RLMD shares outstanding is up +12.77% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.17
RLMD beta is 0.17

200-day SMA

$1.95
RLMD price is currently -84.18% below its 200-day simple moving average

50-day SMA

$0.29
RLMD price is currently +5.08% above its 50-day simple moving average

RSI

55.93
RLMD 14-day relative strength index is 55.93

Volume

0.68
RLMD 30-day relative volume is 0.68

ATR

$0.03
RLMD average true range is $0.03

10-day Historical Volatility

97.73%
RLMD 10-day historical volatility is 97.73%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
RLMD annual revenue value is unknown

Revenue Analysts estimate

-
RLMD annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
RLMD annual revenue 1-year change is unknown

Revenue Sector rank

-
RLMD annual revenue is unknown

EPS

EPS

-$2.65
RLMD annual earnings per share is -$2.65

EPS Analysts estimate

-$0.95
RLMD annual earnings per share is currently +178.95% higher than the consensus analysts' forecast

EPS 1-year change

+19.21%
RLMD annual earnings per share is up +19.21% year-on-year

EPS Sector rank

32.81%
RLMD annual earnings per share is higher than 32.81% of companies in Healthcare sector

Profit

Gross profit

-
RLMD annual gross profit value is unknown

Gross margin

-
RLMD annual gross profit margin value is unknown

Operating profit

-$83.89M
RLMD annual operating income is -$83.89 million

Operating margin

-
RLMD annual operating profit margin value is unknown

Net income

-$79.98M
RLMD annual net profit is -$79.98 million

Net margin

-
RLMD annual net profit margin value is unknown

Expenses

Total expenses

$83.89M
RLMD annual total expenses is $83.89 million

Operating expenses

$83.89M
RLMD annual total operating expenses is $83.89 million

Cost of goods sold

-
RLMD annual cost of goods sold value is unknown

Selling, general & administrative expenses

$37.72M
RLMD annual SGA is $37.72 million

Depreciation and amortization

-
RLMD annual depreciation & amortization value is unknown

Interest expense

-
RLMD annual interest expense value is unknown

Income tax

-
RLMD annual income tax value is unknown

EBIT & EBITDA

EBIT

-$83.89M
RLMD annual earnings before interest & taxes is -$83.89 million

EBITDA

-$83.89M
RLMD annual EBITDA is -$83.89 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$45.82M
RLMD annual total assets is $45.82 million

Non current assets

$22.00K
RLMD annual long term assets is $22.00 thousand

Current assets

$45.80M
RLMD annual total current assets is $45.80 million

Cash and cash equivalents

$3.86M
RLMD annual cash & cash equivalents is $3.86 million

Accounts receivable

-
RLMD annual accounts receivable value is unknown

Inventory

-
RLMD annual inventory value is unknown

Liabilities

Total liabilities

$10.30M
RLMD annual total liabilities is $10.30 million

Long term liabilities

$4500.00
RLMD annual total long term liabilities is $4500.00

Current liabilities

$10.29M
RLMD annual total current liabilities is $10.29 million

Accounts payable

$4.13M
RLMD annual accounts payable is $4.13 million

Debt

Total debt

$0.00
RLMD annual total debt is $0.00

Total debt 1-year change

0%
RLMD {parameterFullLabel} has remained unchanged year-on-year

Long term debt

-
RLMD annual long term debt value is unknown

Short term debt

-
RLMD annual short term debt value is unknown

Equity & Capital

Shareholders equity

$35.52M
RLMD annual stockholders equity is $35.52 million

Book value

$35.52M
RLMD annual book value is $35.52 million

Retained earnings

-$640.88M
RLMD annual retained earnings is -$640.88 million

Working capital

$35.50M
RLMD annual working capital is $35.50 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$51.76M
RLMD annual cash flow from operations is -$51.76 million

Cash from operations 1-year change

-0.19%
RLMD annual cash flow from operations is down -0.19% year-on-year

Cash from investing

$51.56M
RLMD annual cash flow from investing activities is $51.56 million

Cash from investing 1-year change

+2.2%
RLMD annual cash flow from investing activities is up +2.2% year-on-year

Cash from financing

-$40.30K
RLMD annual cash flow from financing activities is -$40.30 thousand

Cash from financing 1-year change

+59.09%
RLMD annual cash flow from financing activities is up +59.09% year-on-year

CAPEX

CAPEX

-
RLMD annual capital expenditures value is unknown

CAPEX 1-year change

-
RLMD annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$51.76M
RLMD annual free cash flow is -$51.76 million

Free cash flow 1-year change

-0.19%
RLMD annual free cash flow is down -0.19% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
RLMD annual gross profit margin value is unknown

Operating margin

-
RLMD annual operating profit margin value is unknown

Net margin

-
RLMD annual net profit margin value is unknown

ROA & ROE

ROA

-174.56%
RLMD annual return on assets is -174.56%

ROE

-225.15%
RLMD annual return on equity is -225.15%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
RLMD price to earnings ratio value is unknown

PE ratio Sector rank

-
RLMD price to earnings ratio is unknown

PB Ratio

PB ratio

0.29
RLMD price to book ratio is 0.29

PB ratio Sector rank

22.72%
RLMD price to book ratio is higher than 22.72% of companies in Healthcare sector

PS Ratio

PS ratio

-
RLMD price to sales ratio value is unknown

PS ratio Sector rank

-
RLMD price to sales ratio is unknown

Enterprise value

Enterprise value

$6.37M
RLMD enterprise value is $6.37 million

Enterprise value Sector rank

20.51%
RLMD enterprise value is higher than 20.51% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.08
RLMD EV/EBITDA is -0.08

EV/EBITDA Sector rank

62.49%
RLMD EV/EBITDA is higher than 62.49% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

4.45
RLMD annual current ratio is 4.45

Quick ratio

-
RLMD annual quick ratio value is unknown

Leverage

Debt to equity

0.00
RLMD annual debt to equity ratio is 0.00

Interest coverage ratio

-
RLMD annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
RLMD piotroski f-score value is unknown

Altman Z-Score

-
RLMD altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Dec 5, 24 Mizuho
Neutral
Dec 4, 24 Leerink Partners
Market Perform
Jun 5, 24 Goldman Sachs
Sell
Jun 15, 23 Mizuho
Buy
Jan 23, 23 SVB Leerink
Outperform
Oct 14, 22 Guggenheim
Neutral
Oct 14, 22 Goldman Sachs
Neutral
Oct 13, 22 Oppenheimer
Perform
Sep 23, 22 Goldman Sachs
Buy
Sep 6, 22 Guggenheim
Buy

Institutional Ownership

Similar stocks

BSGM logo
BioSig Technologies (BSGM)
Kindly MD (KDLY)
NERV logo
Minerva Neurosciences (NERV)
BTCY logo
Biotricity (BTCY)
MGRX logo
Mangoceuticals (MGRX)
TLPH logo
Talphera (TLPH)
ERNA logo
Eterna Therapeutics (ERNA)
BMRA logo
Biomerica (BMRA)
XTLB logo
XTL Biopharmaceuticals (XTLB)
  • What is the ticker symbol for Relmada Therapeutics?
  • Does Relmada Therapeutics pay dividends?
  • What sector is Relmada Therapeutics in?
  • What industry is Relmada Therapeutics in?
  • What country is Relmada Therapeutics based in?
  • When did Relmada Therapeutics go public?
  • Is Relmada Therapeutics in the S&P 500?
  • Is Relmada Therapeutics in the NASDAQ 100?
  • Is Relmada Therapeutics in the Dow Jones?
  • When was Relmada Therapeutics's last earnings report?
  • When does Relmada Therapeutics report earnings?
  • Should I buy Relmada Therapeutics stock now?

What is the ticker symbol for Relmada Therapeutics?

The ticker symbol for Relmada Therapeutics is NASDAQ:RLMD

Does Relmada Therapeutics pay dividends?

No, Relmada Therapeutics does not pay dividends

What sector is Relmada Therapeutics in?

Relmada Therapeutics is in the Healthcare sector

What industry is Relmada Therapeutics in?

Relmada Therapeutics is in the Biotechnology industry

What country is Relmada Therapeutics based in?

Relmada Therapeutics is headquartered in United States

When did Relmada Therapeutics go public?

Relmada Therapeutics's initial public offering (IPO) was on June 20, 2014

Is Relmada Therapeutics in the S&P 500?

No, Relmada Therapeutics is not included in the S&P 500 index

Is Relmada Therapeutics in the NASDAQ 100?

No, Relmada Therapeutics is not included in the NASDAQ 100 index

Is Relmada Therapeutics in the Dow Jones?

No, Relmada Therapeutics is not included in the Dow Jones index

When was Relmada Therapeutics's last earnings report?

Relmada Therapeutics's most recent earnings report was on Mar 27, 2025

When does Relmada Therapeutics report earnings?

The next expected earnings date for Relmada Therapeutics is May 8, 2025

Should I buy Relmada Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page